Market Cap | 78.46B | P/E | 50.78 | EPS this Y | 7.40% | Ern Qtrly Grth | 19.70% |
Income | 1.46B | Forward P/E | 20.09 | EPS next Y | 9.20% | 50D Avg Chg | 7.00% |
Sales | 19.83B | PEG | 2.13 | EPS past 5Y | 2.03% | 200D Avg Chg | 11.00% |
Dividend | 1.00% | Price/Book | 3.05 | EPS next 5Y | 8.65% | 52W High Chg | -4.00% |
Recommedations | 1.80 | Quick Ratio | 1.20 | Shares Outstanding | 289.04M | 52W Low Chg | 28.00% |
Insider Own | 0.28% | ROA | 3.25% | Shares Float | 288.42M | Beta | 0.45 |
Inst Own | 90.03% | ROE | 5.63% | Shares Shorted/Prior | 2.73M/1.48M | Price | 276.24 |
Gross Margin | 44.90% | Profit Margin | 7.13% | Avg. Volume | 1,216,300 | Target Price | 277.87 |
Oper. Margin | 15.13% | Earnings Date | Nov 7 | Volume | 1,396,333 | Change | -0.83% |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Evercore ISI Group | Outperform | Oct 1, 24 |
Citigroup | Buy | Oct 1, 24 |
Raymond James | Outperform | Aug 2, 24 |
Stifel | Buy | Jul 26, 24 |
Citigroup | Neutral | Jul 10, 24 |
Evercore ISI Group | Outperform | Jul 2, 24 |
Goldman Sachs | Buy | May 30, 24 |
Barclays | Overweight | May 6, 24 |
Barclays | Overweight | Feb 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Byrd Richard | EVP & President Inte.. EVP & President Interventional | Nov 28 | Sell | 238.47 | 2,156 | 514,141 | 4,120 | 11/29/23 |
Byrd Richard | EVP & President Inte.. EVP & President Interventional | Sep 05 | Sell | 274.48 | 459 | 125,986 | 3,444 | 09/06/23 |
Fraser Claire | Director Director | Aug 28 | Sell | 281.66 | 848 | 238,848 | 21,608 | 08/30/23 |
Garrison Michael David | EVP & President Medi.. EVP & President Medical | Aug 08 | Sell | 277.13 | 1,300 | 360,269 | 5,157 | 08/09/23 |
Goette Roland | EVP and President, E.. EVP and President, EMEA | Nov 16 | Option | 74.94 | 4,617 | 345,998 | 14,896 | 11/18/22 |
Hickey David | EVP & President, Lif.. EVP & President, Life Sciences | Aug 15 | Sell | 265.00 | 475 | 125,875 | 3,331 | 08/17/22 |
Polen Thomas E Jr | Chairman, CEO and Pr.. Chairman, CEO and President | Aug 15 | Option | 167.91 | 15,000 | 2,518,650 | 43,878 | 08/17/22 |
Polen Thomas E Jr | Chairman, CEO and Pr.. Chairman, CEO and President | Aug 15 | Sell | 265.13 | 9,500 | 2,518,735 | 28,878 | 08/17/22 |
Spoerel Thomas J | VP Controller & Chie.. VP Controller & Chief Acct Off | Jun 07 | Sell | 260 | 443 | 115,180 | 1,058 | 06/09/22 |
Spoerel Thomas J | VP Controller & Chie.. VP Controller & Chief Acct Off | Jun 07 | Option | 147.68 | 1,026 | 151,520 | 2,070 | 06/09/22 |
Hickey David | EVP & President, Lif.. EVP & President, Life Sciences | May 06 | Sell | 256 | 475 | 121,600 | 3,806 | 05/10/22 |
Larson Betty D | EVP HR & CHRO EVP HR & CHRO | Feb 25 | Option | 193.09 | 46,658 | 9,009,193 | 9,556 | 02/28/22 |
Larson Betty D | EVP HR & CHRO EVP HR & CHRO | Feb 25 | Sell | 271.9 | 14,374 | 3,908,291 | 5,872 | 02/28/22 |
Fraser Claire | Director Director | Feb 08 | Sell | 271.70 | 841 | 228,500 | 21,556 | 02/10/22 |
Conroy Alexandre | EVP of Integrated Su.. EVP of Integrated Supply Chain | Feb 03 | Option | 134.73 | 12,787 | 1,722,793 | 34,047 | 02/07/22 |
Conroy Alexandre | EVP of Integrated Su.. EVP of Integrated Supply Chain | Feb 03 | Sell | 270.16 | 6,410 | 1,731,726 | 21,260 | 02/07/22 |
Lim James C | Executive Vice Presi.. Executive Vice President | Sep 07 | Sell | 257.44 | 6,956 | 1,790,753 | 19,768 | 09/07/21 |
Lim James C | Executive Vice Presi.. Executive Vice President | Sep 07 | Option | 134.73 | 14,584 | 1,964,902 | 34,352 | 09/07/21 |